USL255

DRUG2 trials

Sponsors

Upsher-Smith Laboratories

Conditions

Epilepsy

Phase 3

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

CompletedNCT01142193

Upsher-Smith LaboratoriesEpilepsy

Start: 2010-05-31End: 2013-01-31Updated: 2014-05-22

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

CompletedNCT01191086

Upsher-Smith LaboratoriesEpilepsy

Start: 2010-10-31End: 2014-05-31Updated: 2015-02-23

Related Papers

Long-Term Efficacy of USL255 (Qudexy® XR; Topiramate Extended-Release Capsules) by Refractory Status and Age: PREVAIL OLE (P2.054)

Neurology2016-04-05

Neurocognitive Adverse Event Profile of USL255 (Qudexy® XR; Topiramate Extended-Release Capsules): Phase 3 PREVAIL and PREVAIL OLE Studies (P4.222)

Neurology2016-04-05

Long-Term Efficacy, Safety, and Impact on Quality of Life of USL255, Qudexy™ XR (Topiramate) Extended-Release Capsules: PREVAIL OLE (P1.247)

Neurology2015-04-061 citations

Efficacy of once-daily extended-release topiramate (USL255): a subgroup analysis based on the level of treatment resistance.

2014-10-217 citations

Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.

2014-06-0528 citations

Efficacy, Safety, and Impact on Quality of Life of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.261)

Neurology2014-04-081 citations

Use of Investigator Training to Improve Seizure Classification in PREVAIL: A Phase 3, Global Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Adults With Partial-Onset Seizures (P3.280)

Neurology2014-04-081 citations

Long-Term Open-Label Extension (OLE) Study Evaluating USL255, Once-Daily Extended-Release Topiramate, in Patients With Partial Onset Seizures: Interim Analysis From PREVAIL OLE (P3.284)

Neurology2014-04-081 citations

Efficacy of USL255 Across Partial-Onset Seizure Types and Refractory Patient Status: Subgroup Analyses From the PREVAIL Study (P3.263)

Neurology2014-04-08

Early Onset of Efficacy and Safety Outcomes with USL255 Treatment: The PREVAIL Study (P3.264)

Neurology2014-04-08

Comparison of Adverse Effects of USL255 and Commonly Prescribed AEDs: Assessment of Relative Risk (P3.266)

Neurology2014-04-08

Adverse Event Profile of USL255 in Patients with Refractory Partial-Onset Seizures: The PREVAIL Study (P3.262)

Neurology2014-04-08